（Company Code 7702）

Financial Statements
for the Fiscal Year Ended March 31, 2023
(From Apr. 1, 2022 to Mar. 31, 2023)

Summary of consolidated results
May 12, 2023

© JMS CO.,LTD. All Rights Reserved.

Summary of Financial Results
Consolidated

Net sales 63,740 million yen (+5,571 million yen)
Operating profit 724 million yen ((255) million yen)

Increase in sales
Decrease in profit

Sales：

Both domestic and overseas sales increased due to recovery from the effect of COVID-19.
In overseas markets, sales in the Transfusion and Dialysis fields expanded significantly,
and the resulting from yen depreciation increased yen equivalent value, which boosted
net sales.

Profit：Despite the effect of increased sales, profit decreased due to the soaring raw material
prices and electricity costs, as well as increased labor costs in preparation for recovery indemand and increased selling expenses associated with the resumption of sales
activities.

Sales by Business Segment
Transfusion：

Overseas demand for Apheresis kits and Blood bags recovered, which drove sales growth.

Dialysis：

In addition to AV Fistula Needles, a product that is a major product overseas, sales ofHemodialysis Machines also increased.

Sales change by Region
North America：

Apheresis kits and AV Fistula Needles increased. Increased yen equivalent value boosted
net sales.

Asia：

Sales of Blood bags increased, as well as sales of AV Fistula Needles and products related
to the Acute Blood Purification business in China.
Annual dividend: JPY 17 per share (incl. interim dividend JYP 8.5 per share)© JMS CO.,LTD. All Rights Reserved.

2

Highlights in Business Results(unit: JPY million)

Year– over – Year

Apr. - Mar. 2022
ResultsApr. - Mar. 2023
Results

58,16963,740

5,571

9.6%

Operating profit

980

724(255)(26.1)%

Ordinary profit

1,126586(539)(47.9)%

Profit attributable toowners of parent

826

281(545)(66.0)%Net sales

Net sales

Operating profit

Diff.

%

Ordinary profit

Profit attributable toowners of parent

63,74058,05958,56957,57858,169

2,672
2,314

2,127

2,013

1,462
980

Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar.
20192020
2021
2022
2023

1,977

1,520
1,160

1,126
724

Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar.
2019
2020
2021
2022
2023

586

Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar.
2019
2020
2021
2022
2023

© JMS CO.,LTD. All Rights Reserved.

1,736
826
281

Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar. Apr. - Mar.
2019
2020
2021
2022
2023

3

Summary by segment (geographical area)[Japan]Sales increased due to strong sales of Closed Drug Mixing/Infusion System and increased sales related to Acute Blood Purification businessincluding for China market. Profits decreased due to the impact of soaring prices of raw material and electricity costs, as well as increase in
the yen equivalent value of foreign currency-denominated purchase transactions due to yen depreciation and the selling expenses.
[Singapore] Sales of Apheresis kits for North America, Blood bags for Asia, and AV Fistula Needles for affiliates resulted in increased sales. Profits
recovered as the effect of increased sales absorbed the effects of soaring raw material prices and increased labor costs in preparation forrecovery in demand.

(unit: JPY million)

Japan
Singapore※ChinaPhilippines
GermanyOthers※

Year– over – Year

Apr. - Mar.
2022

Apr. - Mar.
2023

Sales

42,69644,573

1,877

4.4%

Ordinary profit

1,083

378(705)(65.1)%

Sales

17,752

22,558

4,806

27.1%

Ordinary profit(75)

159234

―

Sales

3,386

4,088

701

20.7%

Ordinary profit

3579

43122.6%

Sales

3,157

3,716

558

17.7%

Ordinary profit

25185(166)(66.1)%

Sales

3,432

3,749

317

9.2%

Ordinary profit

131

178

4735.9%

Sales

4,059

5,376

1,317

32.5%

Ordinary profit(6)141147―※Singapore : This segment includes Indonesian subsidiary.
※Others : This segment includes business activity of subsidiaries in Japan, United States, South Korea and Thailand.
© JMS CO.,LTD. All Rights Reserved.

Diff.

%

4

Sales by Business Segment(unit: JPY million)

Infusion & Nutrition
23,430 24,221

Apr. - Mar. 2022

Dialysis
Apr. - Mar. 2023

Strong sales of Closed Drug Mixing/Infusion
System and increased sales of blood transfusion
sets to Asia.

18,45020,190Net sales

Net sales

CardiovascularTransfusion

5,286

5,783

Net sales

Apr. - Mar. 2022

Apr. - Mar. 2023

Sales related to Acute Blood Purification businessincreased in Japan and China.

12,025
9,722

Net sales© JMS CO.,LTD. All Rights Reserved.

Apr. - Mar. 2022

Apr. - Mar. 2023

Increased sales of AV Fistula Needles in North
America and China, as well as Hemodialysis
Machines in Japan and China, and Dialysis Therapy
Chairs in Europe.

Apr. - Mar. 2022

Apr. - Mar. 2023

Due to recovery in demand overseas, Apheresis
kits in North America and Blood bags increased
mainly in Asia.

5

Sales change by Region (Customer's Location)
In Japan, sales increased due to growth from the third quarter as a result of recovery in demand.
In Asia, sales increased for Blood Bags, AV Fistula Needles, and Acute Blood Purification Systems.
In North America, growth was driven by AV Fistula Needles and Apheresis kits.

(unit: JPY million)

Year– over – Year

Apr. - Mar.
2022

Apr. - Mar.
2023

Japan

38,24038,526

286

0.7%

60.4%

Asia

8,430

10,869

2,438

28.9%

17.1%

North America

4,486

7,293

2,807

62.6%

11.4%

Europe5,827

5,695(132)(2.3)%

8.9%

Others

1,184

1,355

170

14.4%

2.1%

Diff.

Salescomposition%6© JMS CO.,LTD. All Rights Reserved.

Ordinary profit : Compared with the previous year
Despite the effect of increased sales, gross profit was slightly higher due to the soaring prices of raw materials and electricity costs, as well as
increased labor costs in preparation for recovery in demand.
Selling expenses associated with the resumption of sales activities increased.
Non-operating profits decreased due to a reduction in subsidy income and recording of equity in losses of affiliates.

(unit: JPY million)*The underlined figures exclude impact of exchange rate.

Exchange Rate (average during period)
US Dollar(unit: JPY)EuroSingapore
DollarApr. - Mar. 2022

112.38129.8983.33

Apr. - Mar. 2023

135.47138.04

98.62© JMS CO.,LTD. All Rights Reserved.

7

Forecast for FYE Mar. 2024
Sales：

Demand is recovering both in Japan and overseas. We expect to continue to increase sales by steadily capturing
demand.

Profit：Although we expect to continue to be affected by soaring prices of raw materials and electricity costs, profits areexpected to recover due to the effect of increased sales, further cost reductions, and a review of sales prices andother transaction terms.

(unit: JPY million)FYE Mar. 2022
ResultFYE Mar. 2023
ResultFYE Mar. 2024
Forecast

Year-over-Year%58,16963,74067,0005.1％

Operating profit

980

724

1,000

37.9％

Ordinary profit

1,126

586

1,10087.5％

Profit attributable toowners of parent

826

281

800

184.7％Net sales＊Exchange rate for the forecast: 1USD=130yen, 1EUR=140yen, 1SGD=98yen.

8© JMS CO.,LTD. All Rights Reserved.

TOPICSMarch 2023
Recognized as “Certified Health & Productivity
Management Outstanding Organization”.

We have been continuously working on promoting health management to create anenvironment where employees and their families can live lively and comfortablelives. The certification was granted following the year 2022.

April 2023
Relief Activities in Turkey and Syria Earthquake

Together with our partners, we donated for Turkey, Infusion Sets and needles for theadministration of antibiotics.
9© JMS CO.,LTD. All Rights Reserved.

The Bridge to Good Health Care

The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.